Your browser doesn't support javascript.
loading
Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study.
Urata, Yukitomo; Uesato, Ryoko; Tanaka, Dai; Nakamura, Yoshihide; Motomura, Shigeru.
Affiliation
  • Urata Y; Department of Rheumatology, Seihoku Chuo Hospital, Gosyogawara, Japan. yurata@dream.com
Ann Rheum Dis ; 71(4): 534-40, 2012 Apr.
Article in En | MEDLINE | ID: mdl-22021897
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Severity of Illness Index / Antirheumatic Agents / Matrix Metalloproteinase 3 Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2012 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Severity of Illness Index / Antirheumatic Agents / Matrix Metalloproteinase 3 Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2012 Document type: Article Affiliation country: Country of publication: